Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2017

View Archived Issues

ADV-7103 granted E.U. orphan drug designation for distal renal tubulopathy acidosis

RDD Pharma's RDD-0315 given orphan drug status in E.U.

FDA grants orphan drug designation to BHV-5000 for Rett syndrome

Difolta approved in Japan for peripheral T-cell lymphoma

Trillium Therapeutics identifies EGFR inhibitor

Hypomorphic CARD11 mutations identified in patients with severe atopic disease

Novel nucleoside-analogue inhibitor of RNAP shows promising preclinical antibacterial activity

FDA approves Bristol-Myers Squibb's Orencia in psoriatic arthritis

Titan Pharmaceuticals enters CRADA to evaluate ProNeura antimalarial implants

Catalyst Biosciences achieves milestone in ISU ABXIS collaboration

ProQR Therapeutics receives orphan drug designations in E.U. and U.S. for QRX-411

Shire submits IND to FDA for SHP-654 as treatment of hemophilia A

Phase I study finds S-55746 active in acute myeloid leukemia and myelodysplastic syndromes

Eli Lilly enters partnership with Purdue University

Shire applies for approval of icatibant in Japan

First report of PML-RARG gene fusion in an acute promyelocytic leukemia patient

Anthera opens European screening for phase III study of Sollpura

Conatus announces Novartis' exclusive license for emricasan is now effective

Novel methionine aminopeptidase 2 inhibitors discovered by SynDevRx

Wake Forest, University College Dublin identify new angiotensin (1-7) analogues

SYGNIS completes Innova acquisition

Padlock Therapeutics patents protein-arginine deiminase type-4 inhibitors

University of Queensland, IOCB present novel HGXPRT inhibitors

Janssen decides not to exercise option to Capricor's CAP-1002 in cardiology

ProMIS Neurosciences receives matching grant for research on antibodies targeting Abeta oligomers

Mission Therapeutics discloses novel ubiquitin carboxyl-terminal hydrolase 30 inhibitors

Puma completes targeted enrollment in phase III trial of neratinib for third-line breast cancer

Endo agrees to voluntarily remove Opana ER from market

PET probe [18F]FEONM images Tau in gliomas

Zoliflodacin to begin phase III development for gonorrhea under new partnership

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...